retatrutide phase 2 diabetes trial Survodutide vs. for Weight Loss Effects of retatrutide on body

3, 6, or 12 months

This timeline matches the typical drug development pathway: Phase 3 completion FDA submission 6-12 month review approval commercial manufacturing ramp-up pharmacy distribution

Refrigerate at 28C (3646F) store in the main body of the fridge, not the door (temperature fluctuates more at the door)

Review the injection site reaction guide for detailed management advice

In a phase 2, double-blind, placebo-controlled trial of retatrutide vs placebo (NCT04881760), adults with obesity or with overweight and obesity-related complications but without diabetes who were treated with retatrutide achieved a mean weight reduction of up to 17.5 % at 24 weeks (primary endpoint) and up to 24.2 % at 48 weeks in the 12 mg group